ENNATURE : LISTS ON NSE AND BSE

• Biopharma division of India Glycols reported FY26 net revenue of ₹246 Cr, EBITDA of ₹29 Cr and gross margin of 40.1% • API business is 67% of sales, serving 150+ active customers across 26+ countries; exports 54% of segment revenue in FY26 • Biopolymer segment is 16% of sales, with exports at 69% of FY26 revenue and customers across 23 countries • Nutraceuticals are 17% of sales with five flagship brands and 90+ customers across 19+ countries; exports 83% of revenue • Manufacturing at Dehradun (1,600 MT) and Kashipur (24,000 MT) backed by EU-GMP, CEP, USFDA and NSF-GMP certifications • Nine patents filed, five granted and four under review, plus a research programme of 20 clinical trials • Plans one new API launch annually, expand branded nutraceuticals to six to eight ingredients and deepen US, Europe and Asia distribution

Ennature Bio Pharma Ltd

Open attachment

← Back to feed